{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:48:36Z","timestamp":1793832516360,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.radonc.2026.111710","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:05:44Z","timestamp":1784732744000},"page":"111710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-7874","authenticated-orcid":false,"given":"C\u00e9dric","family":"Draulans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-3673","authenticated-orcid":false,"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-5839","authenticated-orcid":false,"given":"Alfonso","family":"Gomez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9584-637X","authenticated-orcid":false,"given":"Valeria","family":"Faccenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin De","family":"Roover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Scherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-5174","authenticated-orcid":false,"given":"Sophie","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111710_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.radonc.2026.111710_b0010","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0025","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0030","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0035","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","author":"Steinberg","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111107","article-title":"Definition and requirements for stereotactic radiotherapy: a systematic review","volume":"211","author":"Kuncman","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111710_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00656-4","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial","author":"Nilsson","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial","volume":"86","author":"Van As","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111710_b0065","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0070","doi-asserted-by":"crossref","first-page":"e31s","DOI":"10.1200\/JOP.2012.000548","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer","volume":"8","author":"Hodges","year":"2012","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.radonc.2026.111710_b0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2016.11.007","article-title":"Exploring value from the patient\u2019s perspective between modern radiation therapy modalities for localized prostate cancer","volume":"97","author":"Shaverdian","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.zefq.2022.04.025","article-title":"Reporting guidelines for Delphi techniques in health sciences: a methodological review","volume":"172","author":"Spranger","year":"2022","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.radonc.2026.111710_b0085","first-page":"157","article-title":"Advanced prostate cancer consensus conference (APCCC)","volume":"2025","author":"Gillessen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part i: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.03.019","article-title":"Extended follow-up from the stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: updated analysis of 440 patients","author":"Valle","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0100","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1007\/s00345-023-04675-7","article-title":"MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease","volume":"41","author":"Moningi","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0105","doi-asserted-by":"crossref","first-page":"S408","DOI":"10.1016\/j.ijrobp.2014.05.1299","article-title":"Dose-volume analysis of urinary toxicity following SBRT monotherapy for prostate cancer","volume":"90","author":"Seymour","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u226550 cm(3))","volume":"9","author":"Janowski","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0115","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0120","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/j.ijrobp.2021.07.892","article-title":"Stereotactic body radiation therapy for ultra-large (> 100 cc) prostate glands: oncologic, toxicity and patient-reported outcomes","volume":"111","author":"Haas","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0125","article-title":"Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study","author":"Ratnakumaran","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0130","article-title":"Bladder post void residual volume","author":"Ballstaedt","year":"2024","journal-title":"StatPearls"},{"key":"10.1016\/j.radonc.2026.111710_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00555","article-title":"Urinary morbidity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate cancer following transurethral resection of the prostate (TURP)","volume":"10","author":"Pepin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0140","article-title":"Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Front","author":"Woo","year":"2014","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0145","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ijrobp.2025.06.1103","article-title":"Quality of life results from NRG-GU005: a phase III Trial of SBRT vs. Hypofractionated IMRT for localized intermediate risk prostate cancer","volume":"123","author":"Yu","year":"2025","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0150","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0160","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","article-title":"Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial","volume":"73","author":"King","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2023.03.057","article-title":"Every-other-day versus once-a-week urethra-sparing prostate stereotactic body radiation therapy: 5-year results of a randomized phase 2 trial","volume":"117","author":"Zilli","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0190","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0195","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Update of prostate imaging reporting and data system version 2","volume":"2019","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard \u2013 implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0205","article-title":"Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer","author":"Draulans","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2026.111710_b0210","first-page":"11","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"2021","author":"Zamboglou","year":"2021","journal-title":"Sci Reports"},{"key":"10.1016\/j.radonc.2026.111710_b0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the SHARP consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2024.05.009","article-title":"Urinary organs at risk for prostate cancer external beam radiation therapy: contouring guidelines on behalf of the francophone group of urological radiation therapy","volume":"14","author":"Le Gu\u00e9velou","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0225","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature","volume":"41","author":"Le Guevelou","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0230","article-title":"Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity","volume":"46","author":"Ratnakumaran","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0235","article-title":"Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey","volume":"51","author":"Le","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197757","article-title":"Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients","volume":"13","author":"Schaake","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111710_b0245","article-title":"Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: impact on urinary morbidity and mitigation strategies","volume":"45","author":"Huck","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0250","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mp.16878","article-title":"Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): substructure with fraction-wise analysis","volume":"51","author":"Pham","year":"2024","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0255","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2020.01.022","article-title":"Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer","volume":"107","author":"Rasmusson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0260","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.eururo.2017.02.007","article-title":"Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial","volume":"72","author":"Spratt","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111710_b0265","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2023.12.037","article-title":"Urethra-sparing prostate cancer stereotactic body radiation therapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial","volume":"119","author":"Achard","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0270","doi-asserted-by":"crossref","first-page":"S1962","DOI":"10.1016\/S0167-8140(25)00583-3","article-title":"1650 Preliminary results of a phase II randomized control trial of neurovascular-sparing SAbR in localized prostate cancer [PCa] (POTEN-C, NCT03525262)","volume":"206","author":"Desai","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111710_b0280","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2014.58.0662","article-title":"Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910","volume":"33","author":"Pisansky","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0285","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0290","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0295","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111710_b0300","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0310","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0315","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0320","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0325","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0330","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijrobp.2014.10.049","article-title":"Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy","volume":"91","author":"Lovelock","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010013","article-title":"Treatment optimization in linac-based SBRT for localized prostate cancer: a single-arc versus dual-arc plan comparison","volume":"16","author":"Panizza","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111710_b0340","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate advanced radiation technologies investigating quality of life (PARTIQoL): phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110264","article-title":"Photon vs proton hypofractionation in prostate cancer: a systematic review and meta-analysis","volume":"195","author":"Corrao","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0350","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0355","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2021.03.025","article-title":"A multi-institutional phase 2 trial of high-dose SAbR for prostate cancer using rectal spacer","volume":"111","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0365","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaoncol.2022.7592","article-title":"Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial","volume":"9","author":"Mariados","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0370","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijrobp.2025.06.1006","article-title":"Primary results from NRG-GU005: a phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer","volume":"123","author":"Ellis","year":"2025","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0375","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.14624","article-title":"AAPM-RSS medical physics practice guideline 9.b: SRS-SBRT","volume":"26","author":"Cirino","year":"2025","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0380","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1118\/1.598248","article-title":"A technique for the quantitative evaluation of dose distributions","volume":"25","author":"Low","year":"1998","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0385","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/mp.12810","article-title":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","volume":"45","author":"Miften","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0390","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0395","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","article-title":"Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial","volume":"102","author":"de Crevoisier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/1754-9485.12197","article-title":"Assessment of cone beam CT registration for prostate radiation therapy: fiducial marker and soft tissue methods","volume":"59","author":"Deegan","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0405","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fonc.2020.00539","article-title":"Clinical assessment of prostate displacement and planning target volume margins for stereotactic body radiotherapy of prostate cancer","volume":"10","author":"Levin-Epstein","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0410","doi-asserted-by":"crossref","DOI":"10.1002\/mp.18060","article-title":"Real-time monitoring and appropriate margin selection in linac-based prostate SBRT: analysis of two different intrafraction motion monitoring systems","volume":"52","author":"Panizza","year":"2025","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0415","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2016.03.006","article-title":"A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: a multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking","volume":"119","author":"Colvill","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195296","article-title":"Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery","volume":"13","author":"Koike","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111710_b0430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.prro.2023.08.017","article-title":"Monitoring intrafraction motion of the prostate during radiation therapy: suggested practice points from a focused review","volume":"14","author":"Shimomura","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2017.10.029","article-title":"Radiotherapy for prostate cancer - does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? results from a randomized controlled trial","volume":"126","author":"T\u00f8ndel","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0440","unstructured":"Das IJ, Alongi F, Yadav P, Mittal BB. A Practical Guide to MR-Linac Technical Innovation and Clinical Implication n.d."},{"key":"10.1016\/j.radonc.2026.111710_b0445","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-019-1308-y","article-title":"MR-guidance in clinical reality: current treatment challenges and future perspectives","volume":"14","author":"Corradini","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0450","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ijrobp.2020.10.021","article-title":"Adaptive radiation therapy (ART) strategies and technical considerations: a state of the ART review from NRG oncology","volume":"109","author":"Glide-Hurst","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0455","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0460","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijrobp.2025.11.028","article-title":"Primary endpoint analysis of the phase 2 Destination-MRL trial for patients with intermediate-risk prostate cancer","volume":"125","author":"Dassen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111710_b0465","article-title":"A cone-beam computed tomography based workflow for online adaptive ultra-hypofractionated radiotherapy of prostate cancer","volume":"36","author":"Eckl","year":"2025","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111526","article-title":"Identifying high-risk components in online adaptive RT through a multi-centre FMEA to inform clinical trial QA needs","volume":"219","author":"Osman","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0475","first-page":"24","article-title":"PSA bounce, prognosis, and clues to the radiation response","volume":"2021","author":"Kishan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2026.111710_b0480","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.urology.2009.01.043","article-title":"Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon","volume":"74","author":"Caloglu","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2026.111710_b0485","doi-asserted-by":"crossref","first-page":"S1873","DOI":"10.1016\/S0167-8140(25)04392-0","article-title":"9 Prostate-specific antigen bounce after prostate ultra-hypofractionation: associations with 5-year outcomes in the phase 3 trial HYPO-RT-PC","volume":"206","author":"Persson","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111710_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082180","article-title":"Characteristics of PSA bounce after radiotherapy for prostate cancer: a meta-analysis","volume":"12","author":"Darwis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111710_b0495","first-page":"115","article-title":"Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy","volume":"2016","author":"Yamamoto","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2026.111710_b0500","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.radonc.2019.06.023","article-title":"Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: topical review and multicenter consensus","volume":"140","author":"Draulans","year":"2019","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:35:58Z","timestamp":1790714158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":100,"alternative-id":["S0167814026005499"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111710","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111710"}}